Evoke Pharma Cash on Hand 2013-2025 | EVOK
Evoke Pharma cash on hand from 2013 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
|
Evoke Pharma Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2024 | $14 |
| 2023 | $5 |
| 2022 | $10 |
| 2021 | $9 |
| 2020 | $8 |
| 2019 | $6 |
| 2018 | $5 |
| 2017 | $8 |
| 2016 | $9 |
| 2015 | $9 |
| 2014 | $14 |
| 2013 | $24 |
| 2012 | $0 |
| 2011 | $1 |
|
Evoke Pharma Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-09-30 | $12 |
| 2025-06-30 | $12 |
| 2025-03-31 | $13 |
| 2024-12-31 | $14 |
| 2024-09-30 | $11 |
| 2024-06-30 | $9 |
| 2024-03-31 | $10 |
| 2023-12-31 | $5 |
| 2023-09-30 | $6 |
| 2023-06-30 | $7 |
| 2023-03-31 | $8 |
| 2022-12-31 | $10 |
| 2022-09-30 | $12 |
| 2022-06-30 | $13 |
| 2022-03-31 | $8 |
| 2021-12-31 | $9 |
| 2021-09-30 | $11 |
| 2021-06-30 | $17 |
| 2021-03-31 | $18 |
| 2020-12-31 | $8 |
| 2020-09-30 | $6 |
| 2020-06-30 | $8 |
| 2020-03-31 | $4 |
| 2019-12-31 | $6 |
| 2019-09-30 | $7 |
| 2019-06-30 | $7 |
| 2019-03-31 | $4 |
| 2018-12-31 | $5 |
| 2018-09-30 | $7 |
| 2018-06-30 | $7 |
| 2018-03-31 | $5 |
| 2017-12-31 | $8 |
| 2017-09-30 | $10 |
| 2017-06-30 | $13 |
| 2017-03-31 | $15 |
| 2016-12-31 | $9 |
| 2016-09-30 | $10 |
| 2016-06-30 | $4 |
| 2016-03-31 | $6 |
| 2015-12-31 | $9 |
| 2015-09-30 | $11 |
| 2015-06-30 | $10 |
| 2015-03-31 | $12 |
| 2014-12-31 | $14 |
| 2014-09-30 | $12 |
| 2014-06-30 | $16 |
| 2014-03-31 | $22 |
| 2013-12-31 | $24 |
| 2013-09-30 | $24 |
| 2013-06-30 | $1 |
| 2013-03-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |